<DOC>
	<DOCNO>NCT01515423</DOCNO>
	<brief_summary>The purpose study demonstrate paliperidone palmitate 3 month formulation ( PP3M ) effective paliperidone palmitate 1 month formulation ( PP1M ) treatment patient schizophrenia stabilize PP1M .</brief_summary>
	<brief_title>Study Paliperidone Palmitate 3 Month 1 Month Formulations Treatment Patients With Schizophrenia</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double blind ( neither physician patient know treatment patient receives ) , parallel group ( group patient treat time ) , multicenter non-inferiority ( effect new treatment bad comparison treatment ) study . A new formulation paliperidone palmitate 3-month injection interval ( PP3M ) test use maintenance treatment subject schizophrenia first stabilize paliperidone palmitate 1-month injection interval ( PP1M ) . The study consist 3 phase : screening/washout/tolerability phase ( 21 day ) ; 17-week open-label ( people know identity intervention ) stabilization phase ( refer Open-label Phase ) 48-week fix dose , randomize , double-blind control phase ( refer Double-blind Phase ) . After completion Screening Phase , patient receive PP1M Open-label Phase . During time , flexible dose occur Weeks 5 9 . At Week 13 patient receive dose PP1M administer Week 9 . Patients clinically stable end Open-label Phase enter Double-blind Phase randomly assign 1:1 ratio receive fix dos PP3M PP1M .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<criteria>Patients schizophrenia 1 year whose symptom worsen opinion investigator A total score Positive Negative Syndrome Scale ( PANSS ) 70 120 Signed inform consent Women must pregnant , breastfeed , capable pregnancy must practice effective method birth control Men must agree use doublebarrier method birth control Be medically stable basis clinical laboratory test , physical examination , medical history , vital sign , electrocardiogram ( ECG ) A diagnosis schizophrenia , e.g. , dissociative disorder , bipolar disorder , major depressive disorder , schizoaffective disorder , schizophreniform disorder , autistic disorder , primary substanceinduced psychotic disorder , dementiarelated psychosis Relevant history current presence significant unstable medical condition ( ) determine clinically significant Investigator ( ie , obesity , diabetes , heart disease etc ) A diagnosis substance dependence within 6 month screen History neuroleptic malignant syndrome ( NMS ) tardive dyskinesia Clozapine use last 2 month use treatmentresistant treatmentrefractory illness Clinically significant finding biochemistry , hematology , ECG urinalysis result Any disease condition , opinion investigator , would make participation best interest patient could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>R092670</keyword>
	<keyword>Paliperidone Palmitate</keyword>
	<keyword>Paliperidone palmitate 1 month formulation ( PP1M )</keyword>
	<keyword>Paliperidone palmitate 3 month formulation ( PP3M )</keyword>
</DOC>